When it comes to the dense topic of wholesale generic medicine suppliers, it’s naturally best to start by breaking down the complex matter of pricing; specifically, the difference in pricing matters when comparing smaller providers to larger, generic brand providers. There’s been a fair amount of controversy in recent times surrounding the potential consequences of price-fixing power that big household name providers may have over the medicine that they sell.
To date, the majority of America’s states have made heavy strides towards holding the household name wholesale generic medicine suppliers accountable for alleged anti-price restraint agreements made with their supplying manufacturers.
In a late 2017 Philadelphia federal court case, over 40 states produced a nearly 240-page complaint for state attorneys general to file in retaliation to motives that could be contrary to the best interest of economically underserved consumers. Some of the major pharmaceutical players named in the complaint include McKesson, Walgreens Boots Alliance, and other generic providers that capitalize on inflated prices for maximum profit at patients’ expense.
Those contributing to the collective complaint against mainstream generic suppliers have shown heavy investment in customer incentives above all else. In simplest terms, their goal is to create a more economically friendly yet equally inclusive state of prescription drug availability.
Currently, the biggest pharmaceutical players in the game get a major kickback when they’re encouraged to sell their drugs at more heavily inflated prices. The fact of the matter is that so long as the possibility of fewer drug price hikes predicts a damper on the potential profit margins of the mainstream suppliers, price inflation capitalization will continue to be a viable strategy for those in the best position to do so; however, resigning to the best interests of the the major pharmaceutical drug providers’ profit rather than your own budgetary best interests isn’t the only route available to be taken.
Though some of the largest prescription drug providers can seem to have something of a monopoly on what they provide, there are still viable alternatives in the form of perfectly viable, considerably smaller and more personal providers that consumers can reach out to with good results.
By taking a break from the main beaten path and giving less overwhelmingly inflation-padded providers their business, prescription holders may find reprieve from the opportunistic price fixing habits of big-name pharmaceutical powerhouses until the formal complaints lobbied against them gain more traction.